REFERENCES
- Staessen JA, Fagard R, Thijs L, Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757–764.
- Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994;7:7S–12S.
- Selwyn AP, Kinlay S, Creager M, Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease. Am J Cardiol 1997;79:17–23.
- Lijnen HR, Collen D. Endothelium in hemostasis and thrombosis. Prog Cardiovasc Dis 1997;39:343–350.
- Jeng JR, Sheu WH, Jeng CY, Impaired fibrinolysis and insulin resistance in patients with hypertension. Am J Hypertens 1996; 9:484–490.
- Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227:273–278.
- Jeng JR, Sheu WHH, Jeng CY, Impaired fibrinolysis and insulin resistance in patients with hypertension. Am J Hypertens 1996;9:484–490.
- Hamsten A, De Faired U, Wallidus G, Plasminogen activator inhibitor in plasma: risk factor for myocardial infarction. Lancet 1987;2:3–9.
- Vaughan DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol 1997;79:12–16.
- Ridker PM, Gaboury CL, Conlin PR, Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969–1973.
- Brown NJ, Agirbasli MA, Williams GH, Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998;32:965–971.
- Erdem Y, Usalan C, Haznedaroglu IC, Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999;12;1071–1076.
- Fijnheer R, Frijns CJ, Korteweg J, The origin of P‐selectin as a circulating plasma protein.Thromb Haemost 1997;77:1081–1085.
- Michelson AD, Barnard MR, Hechtman HB, In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996; 3:11877–11882
- Sibal L, Agarwal SC, Schwedhelm E, Circulating endothelial progenitor cells, endothelial function, carotid intima-media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbu-minuria. Diabetologia 2009;May 30.
- Munzel T, Sinning C, Post F, Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2008;40:180–196
- Celermajer DS, Sorensen KE, Spiegelhalter DJ, Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994; 24:471–476.
- Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109:III27–32.
- Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. J Gen Intern Med 2002;17:937–945.
- Handler J.Hypertensive urgency. J Clin Hypertens (Greenwich) 2006;8:61–64.
- Chobanian, AV, Bakris, GL, Black, HR, The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003;289:2560–2572.
- Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation 2003;107:579–585.
- Lottermoser K, Weisser B, Hertfelder HJ, Antihypertensive drug treatment and fibrinolytic function. Am J Hypertens 1998;11:378–384.
- Usalan C, Buyukhatipoglu H. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system.Clin Appl Thromb Hemost 2008;14:203–209.
- Mancini GB, Henry GC, Macaya C, Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation 1996; 94:258–265.
- O'Driscoll G, Green D, Rankin J, Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997;100:678–684.